Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
75 participants
INTERVENTIONAL
2015-07-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 Study of OTO-201 in Acute Otitis Externa
NCT02801370
Dose Ranging Study of OTO-201 in AOMT
NCT02719158
Open-Label Study of OTO-201 for Treatment of AOMT
NCT02408796
A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)
NCT04636957
Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora
NCT01027494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.1 mL OTO-201
Ciprofloxacin
OTO-201 (ciprofloxacin)
0.2 mL OTO-201
Ciprofloxacin
OTO-201 (ciprofloxacin)
0.4 mL OTO-201
Ciprofloxacin
OTO-201 (ciprofloxacin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OTO-201 (ciprofloxacin)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a clinical diagnosis of unilateral otitis externa
* Subject or subject's caregiver is willing to comply with the protocol and attend all study visits
Exclusion Criteria
* Subject has a history of known immunodeficiency disease
* Subject has fungal otitis externa, based on clinical signs
6 Months
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otonomy, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carl LeBel, PhD
Role: STUDY_CHAIR
Otonomy, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Email Otonomy Central Contact for Trial Locations
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201-201506
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.